Printer Friendly
The Free Library
14,497,195 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

New newsletter from Mealey's covers arthritis drug litigation.


A hotbed of legal activity has surrounded several drugs used to treat the 20 million Americans with osteoarthritis osteoarthritis
 or osteoarthrosis or degenerative joint disease

Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first.
 and 2 million people struggling with rheumatoid arthritis nationwide. Lawsuits have been filed in a number of juridictions asserting causes of action for injury and death.

To keep litigators and insurance professionals abreast of arthritis drug litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
, Lexis-Nexis Mealey's Publications & Conferences Group has launched Mealey's Litigation Reporter: Arthritis Drugs.

The new $599/year monthly, available both in print and online, covers the latest case news, hard-to-find filings, opinions and pleadings, legislative news, medical studies and FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 reports. It also publishes full-text documents and hosts expert commentary articles written by top-notch attorneys, according to Mealey's marketing manager, Lex Daniele.

"And when stories break between publication dates, we send subscribers e-mail news bulletins to keep them one step ahead of the competition," Daniele said.

Litigators will be able to track litigation involving Vioxx, Celebrex, Enbrel, Arava, Bextra, Kineret, naproxen naproxen and naproxen sodium, potent nonsteroidal anti-inflammatory drugs (NSAID) used to alleviate the minor pain of arthritis, menstruation, headaches, and the like, and to reduce fever. , Remicade, Ridaura, and other related drugs from initial complaint to final appeal.

Editor is Michael Lefkowitz. Mealey's, P.O. Box 62090, King of Prussia King of Prussia, industrialized suburban area (1990 pop. 18,406), Montgomery co., SE Pa. It has glass and steel fabricating, food processing, printing and publishing, and varied manufacturing (textiles, liquified petroleum gas, water-treatment and electrical , PA 19406, 610-768-7800.
COPYRIGHT 2004 The Newsletter on Newsletters LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Newsletter on Newsletters
Date:Aug 6, 2004
Words:182
Previous Article:Strafford Publications launches tax newsletter, acquires health law newsletter.
Next Article:NEPA details the government's "clamps on information release".



Related Articles
MEALEY PUBLICATIONS STARTS TWO LITIGATION REPORTS & RELATED CONFERENCE.
Mealey's newsletter on anti-impotency drugs failed to take off.
Mealey's, bureau of national affairs, M. Lee Smith, and InsiderAdvantage launch new titles.
Mealey's newest title focuses on Baycol[R].
NEPA members "holding their own" and industry sees brisk activity in newsletter launches.
Mealey launches "Emerging Securities Litigation".(Mealey Publications)(Brief Article)
Litigation continues to be rich source of newsletter launches.
Mealey's launches two more litigation letters, one with a related national conference.
New Mealey's Report on Arthritis Drug Litigation.(Brief Article)
Mealey's launches seven titles simultaneously.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles